



Sandra Taylor, Ph.D.
Chief Marketing Officer, PeriGen
(609) 228-8346
Sandra.Taylor@PeriGen.com

PeriGen, Inc. Granted Additional Patents for OB Risk Reduction Technology

Princeton, NJ (May 11, 2011) – PeriGen, Inc., the only OB-specific risk reduction company to provide solutions which generate quantifiable clinical and financial value, today announced that it received additional patents from the United States Patent Office for the technology surrounding its PeriCALM® Shoulder Screen™ solution. The additional patents add to the strength of the Company’s intellectual property portfolio of 16 patents and 21 patents-pending, for proprietary technologies related to its suite of OB clinical support solutions. Emily Hamilton, MD, PeriGen’s senior vice president of research and the creator of the Shoulder Screen tool said, “These patents strongly protect the methods used to assess shoulder dystocia risk. Wide protection, such as this, is possible only when inventions are truly groundbreaking and patent protection is sought early in the discovery process.”

The PeriCALM Shoulder Screen is a web-based application used by obstetricians to identify patients at greatest risk for experiencing shoulder dystocia, a rare and often unforeseeable complication of childbirth. Recent data shows that clinicians who used the Shoulder Screen program to assess patients, experienced a 50% decrease in their rate of shoulder dystocia deliveries, with no increase in the primary cesarean section rate.

“We are pleased to have received additional patents surrounding our Shoulder Screen tool,” said Donald A. Deieso, Ph.D., Chairman and Chief Executive Officer, PeriGen. “We congratulate Dr. Emily Hamilton on a remarkable achievement that positively impacts the health and well-being of mothers and their babies on a daily basis.”

The patented Shoulder Screen tool is currently used by thousands of practicing obstetricians throughout the United States, and promoted by a number of widely-recognized physician insurers. Its detection rates enable better outcomes for obstetricians and multimillion-dollar savings for large hospital systems or insurers.

PeriGen’s suite of technology includes the PeriBirth® clinical decision support system for OB and the PeriCALM fetal monitoring solution. Embedded with artificial intelligence, all of PeriGen’s solutions promote the highest standard of clinical care by ensuring that clinicians have access to the information and guidance they need at both the time and point of care.

About PeriGen, Inc.

PeriGen is a technology-enabled professional services company specializing in risk reduction and clinical quality improvement in Obstetrics and is the only OB-specific risk reduction company to provide solutions which generate immediate, quantifiable and clinical value. Singularly focused on reducing risk and improving financial performance, PeriGen's advanced clinical decision support and fetal monitoring solutions are installed in over 100 hospitals across North America. A pioneer in advanced clinical decision support, PeriGen provides innovative solutions and a full suite of complementary professional and consulting services that reduce risk and improve clinical outcomes. PeriGen is a US corporation headquartered in Princeton, New Jersey, with offices in Canada and Israel. For more information, please visit us at www.perigen.com.